UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 1131, 2019

Novelion Therapeutics Inc.

(Exact Name of Registrant as specified in its charter)

British Columbia, Canada	000-17082	98-0455702
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

c/o Norton Rose Fulbright

1800 - 510 West Georgia Street, Vancouver, BC V6B 0M3 Canada

(Address of principal executive offices)

Registrant’s telephone number, including area code: (877) 764-3131

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, without par value	NVLNF	OTC Markets

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 75.0102. ~~Regulation~~Departure FDof ~~Disclosure~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~Novelion~~On ~~Therapeutics~~December ~~Inc.~~31, ~~(the~~2019, ~~“Company”) issued~~Benjamin aHarshbarger ~~press~~resigned ~~release~~from onhis positions ~~December~~as ~~11,~~the ~~2019~~Interim ~~providing~~Chief anExecutive ~~update~~Officer, onprincipal ~~its~~executive ~~liquidation~~officer ~~process,~~and ~~which~~General isCounsel ~~attached~~of ~~hereto~~Novelion asTherapeutics ~~Exhibit~~Inc. 99(the “Company”), effective immediately.1.

~~The information in~~ Item 78.01 ~~of this Current Report and Exhibit 99~~.1 ~~attached~~Other hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that SectionEvents. Such information shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, unless it is specifically incorporated by reference therein.

~~Item~~As previously announced, on November 18, 2019, the Company filed application materials with the Supreme Court of British Columbia (the “Court”) seeking various orders related to the voluntary liquidation and dissolution of the Company pursuant to the Business Corporations Act (British Columbia) (the “Liquidation”). The foregoing application is scheduled to be heard by the Court on January 9, 2020 (the “Hearing”).~~01. Financial~~ If the Court grants the requested orders at the ~~Statements~~Hearing, the Company intends to file with the British Columbia Registrar of Companies a Statement of Intent to Liquidate indicating that, among other things, the effective date and ~~Exhibits~~time for the commencement of implementation of the Liquidation (the “Effective Date”) will be January 9, 2020 at 5:00 p.m. Pacific Time.

~~(d) Exhibits~~On January 3, 2020, the Company issued a press release providing an update on its liquidation process and related matters, including the Hearing and the Effective Date, which press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

Exhibit No.		Description
99.1		Press Release, dated December 11, 2019 (furnished).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Item 9.01. Financial Statements and Exhibits.

2(d) Exhibits.

SIGNATURES


Exhibit No.		Description
99.1		Press Release, dated January 3, 2020.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~2

~~Novelion Therapeutics Inc. By: /s/ Michael Price Name: Michael Price Title: Executive Vice President & Chief Financial Officer~~SIGNATURES

~~Date: December~~Pursuant 11to the requirements of the Securities Exchange Act of 1934, ~~2019~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

3Novelion Therapeutics Inc. By: /s/ Michael Price Name: Michael Price Title: Executive Vice President & Chief Financial Officer

Date: January 3, 2020

Filing Compare · NOVELION THERAPEUTICS INC.